Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Add as a preferred source on Google
SAN DIEGO, May 08, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, publishes scientific posters with dynamic audio narration. More than a dozen posters were presented at the recent American Association of Cancer Research’s (AACR) 2018 meeting and are now available to watch and download, https://www.crownbio.com/posters/
These scientific posters describe innovations in CrownBio’s Internal R&D focusing on preclinical oncology research. The most compelling work is now available on-demand and narrated by CrownBio scientists. The library of poster presentations includes details on the development and application of several innovative humanized models, a new largescale ex vivo PDX drug screening service and a novel IDO1 inhibition assay platform. Collectively, the data demonstrate CrownBio’s unique capacity to enhance knowledge, guide development decisions and advance immunotherapy programs.
“CrownBio is providing unfettered access to CrownBio’s innovative research with scientific colleagues worldwide,” said Dr. Henry Li, CrownBio’s Vice President of Translational Oncology. “We are committed to sharing with scientists globally the cutting-edge tools that are available to accelerate, inform and enlighten contemporary evaluation of cancer therapies and immunotherapies.”
“Crown Bioscience is committed to making valuable contributions to the scientific community,” said Dr. Jean Pierre Wery, Crown Bioscience’s Chief Executive Officer. “By providing these posters, narrated by the experts behind the science, we hope to deliver insights researchers can use to advance their preclinical drug development programs.”
The library of narrated posters can be found on Crown Bioscience’s website, https://www.crownbio.com/posters/
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
